Drug–drug Interactions Between Direct-Acting Antivirals and Co-Medications: a Territory-Wide Cohort Study

The increasing number of direct-acting antiviral (DAA) regimens along with limited number of subjects and co-medications involved in clinical trials results in drug–drug interactions (DDIs) with DAAs is to be determined. We aimed to examine the prevalence and degree of DDIs between DAAs and other co-medications in a territory-wide cohort of chronic hepatitis C virus (HCV) patients. DDIs were assigned to three risk categories: Category 1—no clinically significant DDI; category 2—potential clinically significant interaction (monitoring and caution required); category 3—contraindicated (should not be co-administered). Of 2981 patients (mean age 59.3 ± 12.3 years; male 60.6